[{"id":"dc906474-83f8-4b00-bb2c-8553f48dae62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03624543","created_at":"2021-01-18T17:48:24.810Z","updated_at":"2025-02-25T14:07:13.959Z","phase":"Phase 2","brief_title":"CFI-400945 in Patients With Advanced/Metastatic Breast Cancer","source_id_and_acronym":"NCT03624543","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • PGR • PTEN","pipe":" | ","alterations":" PTEN mutation","tags":["HER-2 • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ocifisertib (CFI-400945)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-17"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"9eb44888-36d6-498e-87f2-66cdcbe3ea1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02099864","created_at":"2021-01-17T17:57:53.255Z","updated_at":"2025-02-25T15:33:07.009Z","phase":"Phase 2","brief_title":"Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy","source_id_and_acronym":"NCT02099864","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • PTEN • AR • RB1","pipe":" | ","alterations":" PTEN mutation • AR splice variant 7","tags":["TP53 • PTEN • AR • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/05/2014","start_date":" 02/05/2014","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-09-19"},{"id":"ccfd455c-e774-4e0e-bb52-ee525cf236c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592237","created_at":"2021-01-19T20:28:42.436Z","updated_at":"2024-07-02T16:34:58.883Z","phase":"Phase 2","brief_title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04592237","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • TP53 • PTEN • RB1 • CEACAM5","pipe":" | ","alterations":" PTEN mutation","tags":["PD-L1 • TP53 • PTEN • RB1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-04"},{"id":"b82d5afc-83e5-4037-9280-7d0e4dfd7f17","acronym":"NCI10217","url":"https://clinicaltrials.gov/study/NCT03842228","created_at":"2021-01-18T18:58:03.649Z","updated_at":"2024-07-02T16:35:02.758Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","source_id_and_acronym":"NCT03842228 - NCI10217","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation","tags":["PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"cfc2985f-51c4-4ab9-8232-962b73ff7481","acronym":"NCI-2013-02103","url":"https://clinicaltrials.gov/study/NCT01989585","created_at":"2021-01-18T09:04:22.279Z","updated_at":"2024-07-02T16:35:03.325Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","source_id_and_acronym":"NCT01989585 - NCI-2013-02103","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • BCL2","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K","tags":["PTEN • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/24/2014","start_date":" 03/24/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-16"},{"id":"b32f23eb-9a26-4345-b81c-19e88cc236d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01226316","created_at":"2021-01-18T04:55:40.912Z","updated_at":"2024-07-02T16:35:04.747Z","phase":"Phase 1","brief_title":"Safety, Tolerability \u0026 Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules","source_id_and_acronym":"NCT01226316","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA • PTEN","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PTEN mutation • AKT1 mutation","tags":["HER-2 • ER • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PTEN mutation • AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 04/26/2019","primary_completion_date":" 04/26/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-09"},{"id":"ca9c53ec-c832-4b1c-9e81-bef149f09451","acronym":"","url":"https://clinicaltrials.gov/study/NCT04060394","created_at":"2021-01-18T19:54:03.680Z","updated_at":"2024-07-02T16:35:09.013Z","phase":"Phase 1/2","brief_title":"Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC","source_id_and_acronym":"NCT04060394","lead_sponsor":"Laekna Limited","biomarkers":" PIK3CA • PTEN • BRCA","pipe":" | ","alterations":" PTEN mutation • BRCA mutation","tags":["PIK3CA • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • afuresertib (LAE002) • LAE001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 09/13/2019","start_date":" 09/13/2019","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-04-18"},{"id":"ea2d5bda-236b-4252-a552-4af178a4fd25","acronym":"","url":"https://clinicaltrials.gov/study/NCT04216472","created_at":"2021-01-18T20:31:45.945Z","updated_at":"2024-07-02T16:35:09.837Z","phase":"Phase 2","brief_title":"Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations","source_id_and_acronym":"NCT04216472","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • PTEN mutation","tags":["HER-2 • ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 02/05/2020","start_date":" 02/05/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-12"},{"id":"8a933fa1-ad72-4365-92d4-ccb50f41d3ea","acronym":"PROFECTA-II","url":"https://clinicaltrials.gov/study/NCT04374630","created_at":"2021-01-18T21:08:03.631Z","updated_at":"2024-07-02T16:35:15.070Z","phase":"Phase 2","brief_title":"Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian","source_id_and_acronym":"NCT04374630 - PROFECTA-II","lead_sponsor":"Laekna Limited","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PTEN mutation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • afuresertib (LAE002)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-13"},{"id":"366da270-8f09-44d6-be12-90adac16a8b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085729","created_at":"2023-10-17T15:12:33.301Z","updated_at":"2024-07-02T16:35:16.807Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","source_id_and_acronym":"NCT06085729","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1","pipe":" | ","alterations":" TP53 mutation • PTEN mutation • LDH elevation","tags":["TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PTEN mutation • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • cabazitaxel • Hepacid (pegargiminase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-01"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"731ab927-ac32-42ee-9011-baa1124b987d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05229588","created_at":"2022-02-12T17:48:13.004Z","updated_at":"2024-07-02T16:35:21.201Z","phase":"Phase 2","brief_title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","source_id_and_acronym":"NCT05229588","lead_sponsor":"HonorHealth Research Institute","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-02-02"},{"id":"4c92b32e-341b-4687-bdb2-e542cce6f6c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04821141","created_at":"2021-03-29T11:52:25.247Z","updated_at":"2024-07-02T16:35:22.098Z","phase":"Phase 2","brief_title":"Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens","source_id_and_acronym":"NCT04821141","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2 • PTEN • STK11 • NF1 • CDH1 • CHEK2 • NBN","pipe":" | ","alterations":" PTEN mutation • PALB2 mutation • CHEK2 mutation • NBN mutation","tags":["BRCA1 • BRCA2 • PTEN • STK11 • NF1 • CDH1 • CHEK2 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • PALB2 mutation • CHEK2 mutation • NBN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-01-26"},{"id":"1a9ba512-654a-45e0-8404-1839af2f4f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT04552613","created_at":"2021-01-18T21:46:03.074Z","updated_at":"2024-07-02T16:35:23.387Z","phase":"","brief_title":"Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients","source_id_and_acronym":"NCT04552613","lead_sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","biomarkers":" EGFR • KRAS • TP53 • PTEN • RB1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • EGFR mutation • EGFR T790M • PTEN mutation","tags":["EGFR • KRAS • TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • EGFR mutation • EGFR T790M • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 09/24/2023","primary_completion_date":" 09/24/2023","study_txt":" Completion: 09/24/2023","study_completion_date":" 09/24/2023","last_update_posted":"2024-01-15"},{"id":"49e68145-ee70-4d53-9957-c38dd7f689fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01034033","created_at":"2021-01-18T04:03:34.909Z","updated_at":"2024-07-02T16:35:24.040Z","phase":"","brief_title":"Genetic \u0026 Pathological Studies of BRCA1/BRCA2: Associated Tumors \u0026 Blood Samples","source_id_and_acronym":"NCT01034033","lead_sponsor":"Stanford University","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • CDH1","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 3300","initiation":"Initiation: 08/01/2001","start_date":" 08/01/2001","primary_txt":" Primary completion: 01/01/2099","primary_completion_date":" 01/01/2099","study_txt":" Completion: 01/01/2099","study_completion_date":" 01/01/2099","last_update_posted":"2024-01-09"},{"id":"05b7b675-d0e8-4ac1-8f2e-b18c95b14ddf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206203","created_at":"2021-01-18T15:48:15.968Z","updated_at":"2024-07-02T16:35:24.236Z","phase":"Phase 2","brief_title":"Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer","source_id_and_acronym":"NCT03206203","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • PIK3CA • PGR • BRCA1 • BRCA2 • PTEN • BRCA • INPP4B","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • PTEN mutation","tags":["HER-2 • ER • PIK3CA • PGR • BRCA1 • BRCA2 • PTEN • BRCA • INPP4B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 08/29/2017","start_date":" 08/29/2017","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 11/15/2024","study_completion_date":" 11/15/2024","last_update_posted":"2024-01-08"},{"id":"ff7c1831-8767-420c-a63e-fc4a8e3a8271","acronym":"","url":"https://clinicaltrials.gov/study/NCT04042831","created_at":"2021-01-18T19:49:54.652Z","updated_at":"2024-07-02T16:35:33.579Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","source_id_and_acronym":"NCT04042831","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/24/2020","start_date":" 06/24/2020","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2023-10-13"},{"id":"7d51a185-b11f-400c-ae68-d324a30c60b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02068092","created_at":"2021-01-18T09:31:32.582Z","updated_at":"2024-07-02T16:35:34.116Z","phase":"Phase 2/3","brief_title":"Olive Oil for High Risk Breast Cancer Prevention in Women","source_id_and_acronym":"NCT02068092","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • BRCA","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • BRCA mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2023-10-10"},{"id":"6f327e64-d115-4ce3-9cf0-d18bfa2173a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03803761","created_at":"2021-01-18T18:48:06.877Z","updated_at":"2024-07-02T16:35:35.810Z","phase":"Phase 1/2","brief_title":"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer","source_id_and_acronym":"NCT03803761","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PIK3CA • PTEN","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation","tags":["HER-2 • ER • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/13/2019","start_date":" 02/13/2019","primary_txt":" Primary completion: 02/19/2022","primary_completion_date":" 02/19/2022","study_txt":" Completion: 02/19/2022","study_completion_date":" 02/19/2022","last_update_posted":"2023-09-25"},{"id":"ea259fb5-3f93-4045-aa2d-a83218c93202","acronym":"","url":"https://clinicaltrials.gov/study/NCT01141309","created_at":"2021-01-18T04:32:19.305Z","updated_at":"2024-07-02T16:35:42.533Z","phase":"Phase 2","brief_title":"Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer","source_id_and_acronym":"NCT01141309","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTEN • TG","pipe":" | ","alterations":" PTEN mutation • MTOR mutation","tags":["PTEN • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-19"},{"id":"68aa0036-1540-4538-858b-bf876fa2e9ec","acronym":"RACING","url":"https://clinicaltrials.gov/study/NCT03745430","created_at":"2021-01-18T18:20:40.965Z","updated_at":"2025-02-25T14:27:50.093Z","phase":"Phase 1/2","brief_title":"RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03745430 - RACING","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9","pipe":" | ","alterations":" EGFR mutation • PTEN mutation","tags":["PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 04/23/2023","study_completion_date":" 04/23/2023","last_update_posted":"2023-05-24"},{"id":"d6c66296-2fa3-4acd-b1bc-50dce3476783","acronym":"PROGECT","url":"https://clinicaltrials.gov/study/NCT02302742","created_at":"2021-01-17T17:54:38.897Z","updated_at":"2024-07-02T16:35:48.688Z","phase":"","brief_title":"Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry","source_id_and_acronym":"NCT02302742 - PROGECT","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2 • PTEN • BRCA","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • PALB2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • PALB2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1500","initiation":"Initiation: 03/22/2011","start_date":" 03/22/2011","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-05-09"},{"id":"ea90660c-49af-4b83-829a-76d449a7f624","acronym":"","url":"https://clinicaltrials.gov/study/NCT00281658","created_at":"2021-01-18T00:57:33.665Z","updated_at":"2024-07-02T16:35:55.790Z","phase":"Phase 3","brief_title":"Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2","source_id_and_acronym":"NCT00281658","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PIK3CA • PTEN • KIT","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • PIK3CA mutation • PTEN mutation • PTEN-L","tags":["HER-2 • PIK3CA • PTEN • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • PIK3CA mutation • PTEN mutation • PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 444","initiation":"Initiation: 01/02/2006","start_date":" 01/02/2006","primary_txt":" Primary completion: 06/18/2010","primary_completion_date":" 06/18/2010","study_txt":" Completion: 11/23/2021","study_completion_date":" 11/23/2021","last_update_posted":"2023-02-10"}]